LG AI Research Announces Collaboration with D&D Pharmatech to accelerate next-generation oral peptide drug discovery

LG AI Research and D&D Pharmatech just teamed up to shake up oral peptide discovery. Both groups want to crack the code on next-gen research compounds that don’t rely on injections. If you work with peptides, you know oral delivery is the holy grail: easier study designs, better compliance, and way more research flexibility.

The buzz here is about artificial intelligence doing the heavy lifting. LG’s AI division brings machine learning muscle, while D&D Pharmatech has the biochemistry know-how. The goal? Faster, more accurate prediction of which peptide candidates can survive the brutal conditions of the digestive system and still do their job.

This isn’t about one peptide — it’s a leap forward for the whole field. If they nail the oral delivery problem, researchers could:

There’s a lot happening behind the scenes, too. AI-driven peptide design means you can screen hundreds of variants in silico before making a single batch in the lab. That’s a big win for efficiency and cost.

Key takeaway: Peptide research is moving fast, and collaborations like this are breaking old bottlenecks. Oral peptides open doors for all kinds of studies that just weren’t practical before.

Want to see how oral delivery fits into the bigger picture? Check out the peptide research index for a deep dive on current breakthroughs. This partnership is one to watch if you care about the future of peptide science.